the tripeptidyl peptidase 1 (TPP1)/CLN2 gene, resulting in TPP1 enzyme deficiency and subsequent accumulation of lipopigments (lipofuscin) in neurons and other tissues.
The clinical and histological features of NCLs were first described by Batten in 1903, 1 followed by descriptions of its late infantile onset 2 and further clinical characteristics. 3 The late infantile form of the disease is characterized by the onset of epilepsy between the ages of 2 and 4 years. Although the development of myoclonic seizures is the characteristic feature of the disease, children may be referred for speech and language therapy before epilepsy onset, and different types of seizures (including febrile, generalized tonic-clonic, absence, and focal with or without secondary generalization) may occur before myoclonic seizures. 4 As neurodegeneration progresses, seizures become more frequent and often fail to respond completely to medication, and developmental skills (e.g., gross and fine motor control, play, independence, cognitive skills, and vision) are lost. Disease progression is often rapid (occurring over 6-8 months) , with loss of independent mobility and language by the age of 4-5 years. Subsequent regression of psychomotor skills and total loss of vision occur over the next few years, with patients often becoming wheelchair-bound before dying between the ages of 8 and 12 years. 5 Over the past decade, there have been improvements in the understanding of the underlying pathophysiology of NCLs, 5 development of reliable animal models, 6 and therapeutic success in these animal models. 7, 8 It is important to gain further insight into the etiology of CLN2 disease as more trials are set up and treatments become available.
Early diagnosis is critical in CLN2 disease, because irreversible damage occurs between the onset of the disease and its diagnosis; findings from animal studies have shown that early treatment is positively associated with clinical outcome. 9 Unfortunately, early diagnosis is hampered by a lack of reliable disease markers, low disease awareness, and limited access to diagnostic testing in some areas. 10 Early attempts to improve the diagnosis of CLN2 disease suggested that electroencephalography (EEG) might represent a sensitive diagnostic approach, [11] [12] [13] but this approach was abandoned with the appearance of specific molecular and enzymatic diagnostic methods. Given that alterations in enzyme patterns are likely to affect the metabolism of cells responsible for cerebral electrogenesis, electrophysiological changes (i.e., specific EEG features) could still provide useful markers of cerebral metabolic alterations and useful diagnostic information. One EEG feature known to indicate an NCL diagnosis is a photoparoxysmal response (PPR), a paroxysmal spike-wave response, to intermittent photic stimulation (IPS), which involves flashing light on and off for a set duration at escalating frequencies. These EEG findings, initially described by Pampiglione et al., 11, 14 are not unique to NCLs but there are some PPR features that are suggestive of CLN2 disease. The PPR is generally seen in the patient's initial EEG; the spike-wave response is time locked to the photic stimuli, and the response occurs at low-frequency IPS (1-3 Hz). 15 Although a PPR is most commonly reported at low IPS frequencies in CLN2 disease, it has also been reported at middle and high frequencies. 16 It would be beneficial if PPR features could be used as a marker for NCLs, as EEGs are performed for all patients who present with seizures, whereas other tests (e.g., visual evoked potential, electroretinography, and electron microscopy) are not performed unless NCLs are suspected. Previous studies of EEG characteristics in patients with CLN2 disease, however, did not collect comprehensive data. 11, 13, 17, 18 Early diagnosis of CLN2 disease based on EEG findings could provide the key to early treatment, and optimized care and outcomes. The aim of this study, therefore, was to identify early clinical, magnetic resonance imaging (MRI), and EEG characteristics to allow an early diagnosis of CLN2 disease.
Methods
This study was a retrospective clinical chart review of a series of patients diagnosed with CLN2 disease from 2005 to 2015 at the Bambino Ges u Children's Hospital in Rome, Italy. Data were collected from a review of clinical charts, including clinical findings and neuroradiological and electrophysiological features. The following specific data were collected:
• Clinical variables: presenting symptom, other symptoms (e.g., speech delay, ataxia, and regression), age at presentation of each symptom, seizure semiology, motor and cognitive dysfunction, response to antiepileptic and other drugs, and type of diagnosis (molecular and/or enzymatic).
• EEG correlates: age at each EEG, whether IPS was performed, presence of PPR, frequency (in hertz) of PPR, and presence or absence of a flash-per-flash response on IPS. To be suitable for inclusion in the study, at least one EEG for each patient had to have been performed using standardized methods. The international 10-20 system of electrode placement was used to record EEGs. IPS was performed using a Grass PS40 photic stimulator (a rectangular xenon lamp giving flashes of 10-ls duration, 0.7 J/ flash, luminance = 50 cd/m 2 , width = 7 cm, length = 12 cm; Grass Telefactor, U.S.A.) and a Grass PS33 plus stimulator (a round xenon lamp giving flashes of 10-ls duration, 1 J/flash, luminance = 100 cd/m 2 , diameter = 14 cm; Grass Telefactor). Patients sat at a distance of 30 cm from the photic stimulator and were asked to look at the center of the lamp. Ambient lighting was minimized (to approximately 50 lux), but was sufficient to facilitate observation of the patient while controlling ocular fixation on the center of the lamp and to note any subtle clinical ictal phenomena. Separate trains of flashes of 5-s duration were used at the following frequencies: 1, 2, 6, 8, 10, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 40, 50 , and 60 Hz. Flash trains were separated by a pause of at least 7 s. IPS was used to assess the lowest (starting at, and increasing from 1 Hz) and highest (starting at, and decreasing from 60 Hz) frequencies evoking a generalized PPR. These ranges were assessed in three distinct eye conditions in the same sequence for all patients: eye closure, eyes closed, and eyes open. To discriminate between spontaneous and IPS-evoked discharges, the EEG was initially recorded without IPS for at least 2.5 min with eyes open and another 2.5 min with eyes closed. All tracings were reanalyzed retrospectively. Descriptive statistics were used to summarize group data, as appropriate.
Key Points
Informed consent was obtained for all patients, and the study was approved by the ethical committee at the Bambino Ges u Children's Hospital in Rome, Italy. The study conforms to the principles of the Declaration of Helsinki.
Results
A total of 14 patients (eight females) diagnosed with CLN2 disease were included in the study. Diagnosis was confirmed in all 14 patients (100%) using molecular methods and in 10 of 14 patients (71%) using enzymatic methods. The mean age at diagnosis was 4.2 (3.1-5.2) years.
For the group as a whole, median (range) duration of follow-up was 4.3 (2.9-9.9) years. The median age at disease onset was 3.0 (2.0-3.8) years. Epilepsy was the most commonly reported presenting symptom; the symptoms that led to the first evaluation by a pediatric neurologist were epilepsy in 50% (seven of 14) of patients, delayed speech in 79% (11 of 14), regression of acquired milestone skills in 14% (two of 14) , and balance disorders in 14% (two of 14). Semiology of the first seizure was myoclonic in 36% (five of 14), followed by generalized tonicclonic in 29% (four of 14), atonic in 21% (three of 14) , and focal with motor signs in 14% (two of 14). Epilepsy had presented in all cases by a median age of 3.2 (2.6-3.8) years. In two patients, there was a history of febrile seizure before the onset of other symptoms; in both cases, the duration of this seizure was <5 min but presentation was atypical (absence and hemiclonic). All patients (100%; 14 of 14) were walking independently at a median age of 12.0 (11.0-18.0) months. First words were spoken at a median age of 13.3 (12.0-24.0) months, but delayed speech or regression of acquired verbal skills was present in 100% (14 of 14) of patients at the age of 3 years. Clinical and MRI characteristics for individual patients are summarized in Table 1 .
Analysis of EEGs, performed at the median age of 4.0 (3.1-5.1) years, revealed a PPR in 93% (13 of 14) of patients, and PPR was present from the first EEG in 43% (six of 14). The first IPS was performed at a median of 4 (0-23) months after the first EEG; the median delay between first EEG with IPS and first PPR observation was 0.1 (0.1-1.4) years (Fig. 1) . PPR was documented at low stimulation frequencies in 69% (nine of 13) of patients, and the PPR took the form of a flash-per-flash response in 69% (nine of 13). An example of a flash-per-flash response is shown in Fig. 2 . EEG characteristics for individual patients are summarized in Table 2 . For the majority of patients, IPS was not performed at the first EEG.
Early and follow-up EEGs were available for 93% (13 of 14) of patients. With regard to findings in the first EEG, background activity was normal in 46% (six of 13) of patients, and was slow and/or poorly organized, and asymmetric, in the remaining 54% (seven of 13). Focal abnormalities were present in 77% (10 of 13); these were mainly epileptiform in all cases, and four of these patients (31%; four of 13) also had slow focal abnormalities. The focal abnormalities were located predominantly in the temporal lobe with bilateral expression (54% [seven of 13] of patients had activity in the temporal lobe, 15% [two of 13] had activity in the parietal lobe, and 8% [one of 13] had activity in the frontal lobe). In 80% (eight of 10) of patients with focal abnormalities, the focal discharges were isolated, whereas the other 20% (two of 10) showed more repetitive and grouped patterns of abnormalities; 15% (two of 13) of patients had diffuse abnormalities. Most patients (69%; nine of 13) had a PPR at low (1-3 Hz) IPS frequencies; 54% (seven of 13) had a PPR at medium (5-20 Hz) IPS frequencies (a PPR only occurred at medium IPS frequencies for 23% [three of 13]), and 15% (two of 13) had a PPR at high IPS frequencies (>20 Hz).
As expected, a worsening of cortical electrical activity was observed in EEGs performed at more advanced stages of disease. In particular, background activity tended to become slower with a low voltage and poorly organized activity in all patients. Background activity was also more monomorphic and the asymmetric activity detected in the early phases of disease disappeared. Slow, focal anomalies predominated (present in 71% [10 of 14] of patients, compared with epileptiform discharges in 29% [four of 14]). Abnormalities become diffuse in 64% (nine of 14) of patients and remained focal in 36% (five of 14). IPS frequencies generating a PPR were low to medium in 71% (10 of 14) of patients, whereas 21% (three of 14) had a PPR at all frequencies. In the advanced stages of the disease, we observed an electroclinical response at IPS with myoclonic jerks in 57% (eight of 14) of patients.
Antiepileptic drugs (AEDs) taken in the past and during the first IPS evaluation were recorded (Table 2) ; 70% (10 of 14) of patients were receiving valproic acid (VPA) therapy at the time of the first IPS evaluation.
Visual evoked potential (VEP) was abnormal in 86% (12 of 14) of patients and included prolonged P100 latency in 14% (two of 14), absent waveforms in 14% (two of 14) , and giant VEP in 57% (eight of 14) at the first evaluation, which was performed at a median age of 4.5 (3.8-5.1) years.
Patients were evaluated until a median age of 6.2 (3.9-11.4) years. We found that giant VEP was present in all patients with an early PPR at IPS but no clear-cut correlation was found with background EEG abnormalities.
The first brain MRI was performed at a median age of 3.8 (3.0-5.1) years, and showed evidence of cerebellar atrophy in all patients (100%; 14 of 14) and alteration of the periventricular white matter signal in the posterior hemispheric region in 79% (11 of 14) of patients. Some degree of cerebral atrophy was also present in 43% (six of 14) of patients at the first neuroimaging evaluation, and it was evident in all patients who had advanced stages of disease. Cerebellar atrophy was vermian in all patients (100%; 14 and 14) and hemispheric in only 14% (two of 14). Two patients had a normal first MRI (at the ages of 3.3 and 4.5 years, respectively); both of these MRIs were performed at another cent and were not available for examination. In follow-up MRIs performed at our center (7 and 4 months after the first MRI, respectively), both patients presented alteration of the MRI signal. Fig. 3 shows example brain MRIs from patients with CLN2 disease, illustrating the diffuse white matter hyperintensity in the T 2 -weighted flair sequences that are characteristic of the early and later stages of this disease. The diagnosis of CLN2 disease was confirmed in all 14 patients, but seven patients were found to have been previously misdiagnosed:
• Two patients were misdiagnosed as having DandyWalker syndrome rather than mega cisterna magna secondary to vermian atrophy.
• One patient (with a doubtful history of perinatal trauma but normal developmental milestones until the age of 2 years) was misdiagnosed as having suspected perinatal asphyxia rather than posterior white matter signal alteration.
• Two patients were misdiagnosed as having myoclonicastatic epilepsy (Doose syndrome).
• Two patients were misdiagnosed with generalized epilepsy.
Discussion
This retrospective review of the clinical, EEG, and MRI data in the charts of 14 patients diagnosed with CLN2 disease showed that detection of photosensitivity (a PPR at low IPS frequencies of 1-3 Hz) may facilitate an early diagnosis of late infantile NCLs. Molecular and enzymatic tests should therefore be done promptly to refine the diagnosis. 19 The study also showed that the early clinical characteristics of patients with CLN2 disease included epilepsy, delayed speech, regression of acquired milestone skills, and balance disorders. The present study has some limitations: patients were recruited from a single institution, in a unit highly specialized in epilepsy, in the setting of a reference, pediatric hospital. Furthermore, the sample size is limited and further studies are needed to confirm these findings.
The lack of specific early symptoms along with a general low awareness of CLN2 disease hampers early diagnosis. In the present series of patients, for example, although epilepsy was the most frequently reported presenting symptom, seizure types other than myoclonic were more common. In the months following the first seizure and before the onset of psychomotor regression, the only evidence of progressive neurodegeneration was the development of a PPR in the EEG in response to low (1-3 Hz) frequency IPS. One patient did not demonstrate PPR; this patient was only tested at an advanced stage of disease, so it is unclear whether PPR was present at the early stages. In general, the EEG pattern changed with the progression of disease and neuronal degeneration in this case series. A possible explanation for these EEG changes is that the TPP1 enzyme deficiency underlying CLN2 disease results in alterations in the metabolism of cells responsible for cerebral electrogenesis. This finding has important clinical implications, as this EEG feature could be used as a marker of metabolic alterations within the brain, 19 enabling early diagnosis of CLN2 disease.
In our experience using a standardized IPS method, PPR was a hallmark of the presence of early CLN2 disease in most patients (93%). This finding conflicts with previous studies reporting that PPR was not present in all CLN2 disease patients. 4, 17 However, these studies often failed to use standardized EEG/IPS procedures and did not collect a comprehensive data set, so it is possible that the phenomenon was present but not captured. Although the presence of PPR in response to IPS in patients with CLN2 disease was observed >40 years ago by Pampiglione and Harden, 11 it was not studied systematically in some of the more recent studies. 17, 18 In the large series of 34 patients with CLN2 disease studied by Jadav et al., 17 for example, only two patients were reported to have PPR at 9 and 15 Hz, but it is unclear how IPS was performed and whether this was carried out in all patients. In a Spanish series, PPR was not observed in 12 children from 10 different centers, but once again it is not clear how IPS was performed and in how many patients. 4 Another study conducted in 18 patients with CLN2 disease using standardized EEG reported a large polyspike response to a single flash of light (evoked by IPS) in all patients in whom this test was performed, 13 but again it is unclear how many patients underwent IPS. Furthermore, a PPR has been evident in CLN2 disease in some single case reports. 16, 20, 21 None of the series reported the age at which the presence of PPR was observed or the stage of the disease.
Different responses to different light stimulation frequencies occur in different photosensitive epilepsies, and at different disease stages, making this approach potentially powerful and certainly worthy of further research to improve its diagnostic specificity. A PPR at low IPS frequencies was observed in 69% of patients in the present study, and this was a flash-per-flash response in 69% of patients. This finding is in line with previous reports of PPR (a flash-per-flash response) in patients with CLN2 disease at frequencies < 3 Hz. 13, 15 A reduction in the size of evoked discharges is reported to occur at frequencies of 4 Hz or higher, and PPR is sometimes accompanied by muscle twitches in the limbs and/or face. 12 It would be useful to determine the prevalence of a PPR at low IPS frequency among children of a similar age who do not have CLN2 disease. PPRs to low-frequency stimulation are also known to occur in Lafora disease 22 and mitochondrial disease, 23 as well as in variant late infantile NCL (CLN6). 12, 19 Moreover, light sensitivity might occur in patients of a similar age with other types of epilepsies (e.g., in Dravet syndrome, early photosensitivity is reported in about 10% of cases 24 ). However, the overall prevalence of early photosensitivity is currently unknown.
Responses to IPS may also change with disease progression. Pampiglione and Harden described some patients who did not have PPR at low frequencies at the first EEG, but who did have PPR at medium frequencies at the same EEG, 11 and two patients with CLN2 disease with similar PPR characteristics were also reported by Binelli et al. 12 It is likely that EEG findings that change over time reflect gray matter changes as this neurodegenerative disease progresses.
Response to IPS may also be affected by use of AEDs. VPA is known to reduce photoconvulsive response in humans 25 ; however, we cannot evaluate whether administration of VPA affected the response to IPS in this study, as 70% of patients were already taking the drug at the time of first IPS.
EEGs recorded at the first observation showed some interesting features; approximately half of patients (54%; seven of 13) showed irregular and slow background EEG activity at the early evaluation, and focal epileptiform abnormalities were found in most patients (77%; 10 of 13), predominantly in the temporal lobe (54%; seven of 13 patients) with bilateral expression. A prevalently posterior location of epileptiform anomalies in CLN2 disease has previously been described. 12 Therefore, excluding PPR, other EEG findings in patients with CLN2 disease were not homogeneous; both focal and bilateral abnormalities were found. This is consistent with previous publications, 12, 13, 15 and further investigations should better delineate this finding. The degree of background activity impairment varied in the early stages of disease, and when present, the epileptiform anomalies did not have any distinctive morphology or location in our series of patients.
Regarding MRI findings, cerebellar atrophy was present in 100% (14 of 14) of patients, which is a known finding in CLN2 disease. 17, 26 Cerebellar atrophy combined with alteration of the periventricular white matter signal in the posterior hemispheric region in 79% (11 of 14) of patients may constitute the pattern-recognition approach to CLN2, as previously reported. 27 In addition to these features, cortical degeneration and hypointensity of the thalami have also been described as suggestive of NCLs. 28, 29 With regard to use of IPS in the clinic, it is critical that IPS is conducted correctly and in a standardized way if the technique is to have a role in the accurate diagnosis of photosensitive epilepsies.
12,16,22,23,30,31 Care must be taken to ensure that the lamp remains directly in front of the patient's eyes (even during rapid head movements), and that the correct distance (30 cm) between the eyes and the lamp is maintained. IPS should be performed at the first EEG to optimize understanding of the patient's neurophysiological features and raise suspicion of CLN2 disease as early as possible. This study showed that there was often a delay between the first EEG without IPS and the first EEG with IPS, which reflects a delay in the diagnosis of CLN2 disease. Furthermore, although photosensitivity at low frequencies is indicative of CLN2 disease, particularly when speech is delayed or when MRI abnormalities are present, diagnosis can only be confirmed by TPP1 enzyme testing or CLN2/TPP1 molecular testing. These tests should be considered when other symptoms are present, regardless of the presence or absence of photosensitivity at different frequencies.
This study, therefore, adds new information to what is known about CLN2 disease; the cases presented showed that PPR on low-frequency IPS could be detected in genetically confirmed early stage CLN2 disease. This information has clinical implications, as this EEG feature could be used to indicate metabolic alterations within the brain, enabling early diagnosis of CLN2 disease through molecular and enzymatic tests.
Conclusions
Early photosensitivity (typically PPR at low stimulation frequencies) is a hallmark of CLN2 disease. When this occurs in a child presenting with any type of seizure, and particularly if accompanied by delayed speech and/or ataxia, or when MRI abnormalities (posterior white matter signal alteration or cerebellar atrophy) are present, a diagnosis of CLN2 disease should be considered.
